VandenBerg Amy 4
4 · OBALON THERAPEUTICS INC · Filed Jul 25, 2019
Insider Transaction Report
Form 4
VandenBerg Amy
Chief Clinical & Reg Officer
Transactions
- Award
Stock Option (Right to Buy)
[F1][F2]2019-07-23+35,000→ 35,000 totalExercise: $0.96Exp: 2029-07-23→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]Subject to the grantee's continued status as a service provider with the Issuer through the applicable vesting date, the option shall vest as to 100% of the shares underlying the option on the day following the filing date of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, based on the achievement of performance goals on or prior to December 31, 2019.
- [F2]Share amounts do not reflect the impact of a 1-for-10 reverse stock split that became effective after the grant date for the options referenced herein.
Signature
/s/ Nooshin Hussainy as attorney-in-fact for Amy VandenBerg|2019-07-25